Itovebi Inavolisib Tablets

1. Indications and Usage
Status: Investigational (Clinical Trial Phase).
Target Diseases:
Systemic Lupus Erythematosus (SLE): Evaluation in patients with moderate to severe SLE.
IgG4-Related Disease: Evaluation for organ involvement.
Graves’ Disease / Thyroid Eye Disease: Evaluation for active disease.
2. Dosage and Administration
Route of Administration: Intravenous (IV) Infusion ONLY.
Dosing Schedule:
Typically administered as a single infusion or divided doses (e.g., on Day 1 and Day 8) depending on the specific clinical protocol.
Pre-medication: Corticosteroids and antihistamines are usually administered prior to infusion to mitigate infusion-related reactions.
3. Mechanism of Action
Target: B-Cell-Specific Anti-BAFF Antibody.
Action:
Ianalumab is a human monoclonal antibody that binds to the B-Cell Activating Factor (BAFF), also known as BLyS.
By binding to BAFF, it prevents BAFF from interacting with its receptors (BAFF-R, TACI, BCMA) on B-cells.
This leads to the depletion of mature B-cells and inhibition of B-cell survival and differentiation into autoantibody-producing plasma cells.
4. Safety and Warnings
Infusion-Related Reactions:
Can cause severe infusion-related reactions (fever, chills, hypotension, dyspnea). Infusions should be administered in a setting equipped for emergency resuscitation.
Infections:
Mechanism involves B-cell depletion; patients may be at increased risk for bacterial and viral infections.
Immunoglobulin Levels:
Monitoring of immunoglobulin (IgG) levels is recommended.
5. Adverse Reactions
Most Common (Clinical Trial Data):
Infusion-related reactions.
Upper respiratory tract infections.
Headache.
Pyrexia (Fever).
6. Drug Interactions
Live Vaccines:
Avoid administration of live vaccines during and after treatment until B-cell reconstitution has occurred.
7. Pharmaceutical Information
Chemical Composition:
Active Ingredient: Ianalumab (Recombinant human monoclonal IgG1 antibody).
Appearance: Clear to opalescent, colorless to pale yellow liquid for injection.